-+ 0.00%
-+ 0.00%
-+ 0.00%

First Berlin reiterates Buy on Cardiol Therapeutics, sets USD 7.5 target price

PUBT·04/30/2026 11:14:33
Listen to the news
First Berlin reiterates Buy on Cardiol Therapeutics, sets USD 7.5 target price
  • First Berlin Equity Research reiterated a Buy rating on Cardiol Therapeutics, keeping target price at USD 7.5.
  • Update cited expanded US site network for Phase III MAVERIC trial in recurrent pericarditis, with total US sites seen at about 25.
  • Report said enrollment reached 75%, with full enrollment still targeted for Q2 2026.
  • Analyst modeled headline data readout in Q4 2026, with Q1 2027 flagged as downside scenario if enrollment slips into Q3 2026.
  • Research called MAVERIC results primary stock catalyst over next 12 months, implying upside of more than 470% versus current levels.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_25562), on April 30, 2026, and is solely responsible for the information contained therein.